ISRCTN47219228 https://doi.org/10.1186/ISRCTN47219228

# The use of metformin in patients with polycystic ovarian syndrome requiring treatment with in vitro fertilisation (IVF)

| Submission date | Recruitment status | [ ] Prospectively registered |
|---|---|---|
| 12/09/2003 | No longer recruiting | [ ] Protocol |
| **Registration date** | **Overall study status** | [ ] Statistical analysis plan |
| 12/09/2003 | Completed | [ ] Results |
| **Last Edited** | **Condition category** | [ ] Individual participant data |
| 07/09/2015 | Urological and Genital Diseases | [ ] Record updated in last year |

**Plain English summary of protocol**
Not provided at time of registration

## Contact information

**Type(s)**
Scientific

**Contact name**
Mr Richard Howell

**Contact details**
Fertility Unit
Homerton University Hospital NHS Trust
Homerton Row
London
United Kingdom
E9 6SR
+44 (0)20 8510 7660
abc@email.com

## Additional identifiers

**Protocol serial number**
N0024120995

## Study information

**Scientific Title**

The use of metformin in patients with polycystic ovarian syndrome requiring treatment with in vitro fertilisation (IVF)

## Study objectives
Metformin has been shown to be useful in patients with polycystic ovarian syndrome (PCOS) undergoing IVF. The aim of this study is to investigate whether metformin therapy in patients with polycystic ovaries can improve the fertilisation rates and significantly improve pregnancy rates.

## Ethics approval required
Old ethics approval format

## Ethics approval(s)
Not provided at time of registration

## Study design
Randomised controlled trial

## Primary study design
Interventional

## Study type(s)
Treatment

## Health condition(s) or problem(s) studied
Urological and Genital Diseases: Polycystic ovarian syndrome (PCOS)

## Interventions
Group A will be given 500 mg metformin TDS for 1 month prior to their treatment. Group B will not be treated with metformin. Both groups will undergo standard IVF treatment.

## Intervention Type
Drug

## Phase
Not Applicable

## Drug/device/biological/vaccine name(s)
Metformin

## Primary outcome(s)
1. Total number of folicles reaching 18 mm
2. Number of eggs obtained, number and quality of mature eggs, fertilisation rates
3. Total number of embryos, number and quality of embryos replaced and number of embryos frozen
4. Biochemical pregnancies, clinical pregnancies
5. Number of cycles abandoned for poor response and over response
6. Number of cases of ovarian hyperstimulation in each group

## Key secondary outcome(s))
Not provided at time of registration

**Completion date**
31/12/2005

# Eligibility

**Key inclusion criteria**
Patients with PCOS

**Participant type(s)**
Patient

**Healthy volunteers allowed**
No

**Age group**
Adult

**Sex**
Female

**Key exclusion criteria**
Does not meet inclusion criteria

**Date of first enrolment**
01/01/2003

**Date of final enrolment**
31/12/2005

# Locations

**Countries of recruitment**
United Kingdom

England

**Study participating centre**
**Homerton University Hospital NHS Trust**
London
United Kingdom
E9 6SR

# Sponsor information

**Organisation**
Department of Health (UK)

# Funder(s)

**Funder type**
Government

**Funder Name**
Homerton University Hospital NHS Trust

# Results and Publications

## Individual participant data (IPD) sharing plan

**IPD sharing plan summary**
Not provided at time of registration

**Study outputs**

| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| Participant information sheet | Participant information sheet | 11/11/2025 | 11/11/2025 | No | Yes |